Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff […]
The new blood test, sclero-smart™, measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications. This suggests a link between scleroderma and the gut microbiome, a finding […]
A systematic review and meta-analysis was recently published in the World Journal of Clinical Cases1 that asses the effects of probiotic preparation Medilac-S® (Enterococcus faecium Rosell®-26 and Bacillus subtilisRosell®-179), as adjunctive therapy in ulcerative colitis […]
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close […]
4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings […]
In just a few short years, Rebiotix has taken the concept of “bugs as drugs” and turned it into actual practice, constructing a standardized, stabilized drug product from the broad consortia of microbes present in a […]
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40 […]
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, announced that the […]
Da Volterra, a clinical-stage microbiome company focused on developing new therapeutics to protect the intestinal microbiota, announced today that it has enrolled the first patients in a Phase 2 trial called SHIELD, evaluating its innovative […]
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson […]
Synthetic Biologics, Inc. (NYSE American: SYN), announced that the first two patients have been enrolled in SYN-010’s Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane […]